Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Mutation and Low Expression of ARID1A are Predictive of a Poor Prognosis and High Immune Infiltration in Triple-negative Breast Cancer.

Current cancer drug targets - 1 Jan 2024

Wang Yuejing, Chen Zhuo, Wu Jing, Yan Hong, Wang Yiran, He Jie

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) has the poorest prognosis among all breast cancer subtypes. While several tumor types are excepted to have a curative response to immunotherapy through the AT-rich interaction domain 1A (ARID1A) gene, its role in TNBC remains unclear. METHODS: The expression of the ARID1A gene and immune infiltration in TNBC were analyzed by way and function enrichment analysis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ARID1A gene

Share to Lymphocytes, Tumor-Infiltrating

Share to Mutation

Share to Prognosis

Share to Transcription Factors

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 37221684
DOI: 10.2174/1568009623666230522115229

Genes

ARID1A
CD4
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Mutation and Low Expression of ARID1A are Predictive of a Poor Prognosis and High Immune Infiltration in Triple-negative Breast Cancer.PMID 37221684Read ↗

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitorsSemantic proximity Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer.Semantic proximity Read ↗

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapySemantic proximity Read ↗

ARID1A mutation is associated with an immunosuppressive microenvironment and poor prognosis in hepatocellular carcinoma: An integrated bioinformatics analysis.Semantic proximity Read ↗

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers.Semantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.